Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | XDH | P47989 | 3/20 | 0.36 |
| ▸ | PPIA | P62937 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593140 | 0.91 | XDH (0.38) | ADORA3XDHPPIAMAOBFFAR1 | |
| SCHEMBL6080478 | 0.84 | XDH (0.39) | XDHMAOBEGLN1KMT2ASLC6A2 | |
| Benzene SCHEMBL6592619 | 0.79 | XDH (0.39) | XDHMAOB | |
| SCHEMBL6594157 | 0.77 | XDH (0.40) | XDHMAOB | |
| SCHEMBL6593145 | 0.75 | XDH (0.40) | XDHFFAR1 | |
| SCHEMBL6079768 | 0.75 | ALDH1A1 (0.38) | ADORA3FFAR1TDP1 | |
| SCHEMBL6080444 | 0.74 | XDH (0.38) | ADORA3XDHPPIAMAOB | |
| SCHEMBL6079492 | 0.74 | XDH (0.41) | ADORA3XDHMAOBEGLN1EGLN2 | |
| SCHEMBL6080295 | 0.71 | KDM4A (0.38) | EGLN1KMT2A | |
| SCHEMBL6592610 | 0.70 | XDH (0.49) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | ADORA3 1328/4885XDH 128/4885PPIA 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.